前列腺癌患者组织中RPL6的表达及临床意义.

Objective: To study the expression of Ribosomal protein L6 (RPL6) in the tissues of patients with prostate cancer.and to evaluate the role of the protein in the grade malignancy. Methods: A total of 117 patients with prostate disease, who were treated in First People's Hospital of Guangyuan from December 2013 to December 2015, were selected and divided into prostatitis group (n=63) and prostate cancer group(n=54) according to pathological results; in addition. 80 healthy people who underwent physical examination at the same time were enrolled as normal control group. The expression of RPL6 in the prostate tissue of three groups was detected by Western-blot. Serum tumor markers were detected by Enzyme-linked immunosorbent assay (ELISA). The levels of mKNA expression of proliferation gene and invasion gene were tested by RT-PCR. The relationship between RPL6 expression and malignant degree was analyzed by Pearson test. Results: The levels of RPL6 expression of prostate tissues in the prostate cancer group were higher than those in the prostatitis group and normal control group (P<0.05). The serum contents of prostate specific antigen (PSA), prostatic acid phosphatase (PSAP). urokinase-type plasminogen activator (uPA), and thioredoxin (TRX) in the prostate cancer group were higher than those in the prostatitis group and normal control group (P<0.05). The proliferation genes in the prostate tissues such as URG11 and PTEN mRNA in the prostate cancer group were higher than those in the prostatitis group and normal control group: PRDM5 mRNA expression in the prostate cancer group was lower than that in the prostatitis group and normal control group: the levels of invasion gene expression such as IgGHGl. TMPRSS2-ER. and PIK3C2B mRNA in the prostate cancer group were higher than those in the prostatitis group and normal control group (P<0.05). RPL6 expression in the tissues of prostate cancer patients was directly related to the content of tumor markers, proliferation and invasion genes (P<0.05). Conclusion: High expression of RPL6 is a reliable index for early diagnosis of prostate cancer, and it is directly related to the degree of malignancy, which is expected to be an important tool for the diagnosis and prognosis of prostate cancer. [ABSTRACT FROM AUTHOR]